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Background
Sarcomas are cancers that arise from tissues of mesenchy-
mal origin and there has been limited improvement
in treatments over the last 30 years. The Warburg effect
is a widespread metabolic phenotype of cancer, where
glycolysis is favoured despite the presence of oxygen.
Dichloroacetate (DCA) is a pyruvate dehydrogenase kinase
(PDK) inhibitor in clinical use that can reverse the
Warburg effect, inhibiting growth and enhancing
apoptosis in a range of cancers. We have investigated its
effectiveness against sarcoma cells in vitro and in vivo.
Materials and methods
Three cell lines (mouse fibrosarcoma S180, mouse osteo-
sarcoma K7M2 and human fibrosarcoma HT1080-luc2)
were examined for cell viability after DCA treatment in
vitro (neutral red uptake assay), alone and in combination
with doxorubicin. In vivo, K7M2 cells were injected s.c.
into Rag1-/- mice (2 sites per mouse, 7-9 mice per group)
and established tumours were treated with DCA in the
drinking water (0, 0.5, 1.0 and 1.5 g/L, delivering 0, 70,
125 and 165 mg/kg/day, respectively). Tumour growth
was monitored with callipers. Plasma was collected on d1
and d15 for measurement of DCA levels (LC-MS).
Results
DCA significantly reduced the total viable cell number
after 48 h of treatment in the mouse sarcoma lines (~15%
at 0.5 mM DCA, and 30-40% at 5 mM DCA), however
HT1080-luc2 cells showed only a 10% reduction in cell
number with 5 mM DCA. There was no morphological
indication of apoptosis, suggesting DCA was decreasing
proliferation. Chronic treatment of the mouse cells (5 mM
DCA for 2 weeks) resulted in significantly slower growth
rates as measured over 48 h (7 and 13% total cell number
compared to untreated S180 and K7M2 cells, respectively).
DCA did not synergise with doxorubicin but was additive
at lower concentrations of doxorubicin. In vivo, 1.0 and
1.5 g/L DCA significantly reduced tumour growth (33.0
and 33.1% reduction in tumour size on d13, p=0.001 and
0.01 respectively). Plasma DCA was undetectable on d1 of
treatment, but by d15, 1.0 and 1.5 g/L DCA delivered
2-44 uM. Tumour DCA concentrations were also
measured and found to be in the range of 25-470 uM,
much lower than those typically used in in vitro studies.
Conclusions
DCA was effective against an in vivo sarcoma model, with
tumour DCA concentrations in the micromolar range.
These concentrations are achievable clinically, thus DCA
warrants further investigation for sarcoma treatment.
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